Antipsoriasique And NotJ. D. Kent
List of bibliographic references
Number of relevant bibliographic references: 3.Ident. | Authors (with country if any) | Title |
---|---|---|
001D77 | M. A. Kamm [Australie, Royaume-Uni] ; S. B. Hanauer [États-Unis] ; R. Panaccione [Canada] ; J.-F. Colombel [France] ; W. J. Sandborn [États-Unis] ; P. F. Pollack [États-Unis] ; Q. Zhou [États-Unis] ; A. M. Robinson [États-Unis] | Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease |
002C34 | Jean-Frédéric Colombel [France] ; William J. Sandborn [États-Unis] ; Paul Rutgeerts [Belgique] ; Michael A. Kamm [Australie] ; Andrew P. Yu [États-Unis] ; Eric Q. Wu [États-Unis] ; Paul F. Pollack [États-Unis] ; Kathleen G. Lomax [États-Unis] ; JINGDONG CHAO [États-Unis] ; Parvez M. Mulani [États-Unis] | Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease : Results From the CHARM Trial |
004158 | L. Dubertret [France] ; W. Sterry [Allemagne] ; J. D. Bos [Pays-Bas] ; S. Chimenti [Italie] ; S. Shumack [Australie] ; C. G. Larsen [Norvège] ; N. H. Shear [Canada] ; K. A. Papp [Canada] | Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis : results from a phase III international randomized, placebo-controlled trial |
This area was generated with Dilib version V0.6.33. |